According to The Insight Partners' research, the South and Central America Eye Allergy Treatment Market was valued at US$ 277.3 Million in 2024 and is expected to reach US$ 371.9 Million by 2031, registering a CAGR of 4.4% from 2025 to 2031.
Sustained-release ocular implants and drug-eluting contact lenses and preservative-free, multi-action "smart" eye drops are among the critical factors attributed to drive the South & Central America eye allergy treatment market.
Sustained-release ocular implants involve biodegradable or bioerodible devices inserted into the eye's tear ducts or conjunctiva, providing controlled drug elution over weeks to months. A prime example is DEXTENZA, an FDA-approved intracanalicular dexamethasone insert. When placed in the punctum, it releases corticosteroid steadily for up to 30 days, addressing inflammation without daily drops. Clinical trials demonstrated remarkable efficacy: median ocular itching scores dropped from 2.5 at baseline to 0 by day 30, outperforming topical steroids in hyperemia reduction (p<0.0001) and earning patient preference from 60% of participants over comparators like loteprednol. Safety profiles are strong, with no clinically significant intraocular pressure rises or adverse events reported, highlighting its potential for seasonal allergy flares.
Complementing implants, drug-eluting contact lenses integrate therapeutics into hydrogel matrices, releasing agents directly onto the ocular surface for hours. Johnson & Johnson's ACUVUE Theravision with Ketotifen exemplifies this innovation. These daily disposable lenses embed the antihistamine ketotifen, blocking mast cell degranulation to alleviate itch, redness, and burning sensation within minutes, with effects lasting up to 12 hours while correcting vision. In pivotal trials, 98% of users reported no irritation upon insertion. A retrospective study of seasonal allergic conjunctivitis patients showed lens wearers achieved a superior total symptom score reduction of ?4.7 (vs. ?0.65 for standard lenses; p=0.010), delaying the need for supplemental anti-allergy drops by a median of 57 days (vs. 19; p=0.045). Bioavailability soars to 35-50%, far surpassing drops.
This dual trend addresses adherence barriers, i.e., 93% of eye care providers express willingness to adopt such devices, thereby fostering a shift toward proactive, patient-centric care. Advancements in nanotechnology are optimizing release kinetics, paving the way for broader adoption in chronic allergy management. This evolution promises to alleviate healthcare system pressures while enhancing patient quality of life. Such technologies are poised to become integral to treatment protocols, combining precision with convenience for millions worldwide.
On the contrary, stringent regulatory approvals hamper the growth of the South & Central America eye allergy treatment market.
South and Central America Eye Allergy Treatment Market Segmentation Analysis:
- By Diagnostic, the South and Central America Eye Allergy Treatment Market is segmented into Oral Medication, Allergy Shots, and Eye Drops. The Eye Drops segment is projected to expand at a CAGR of 4.7% during 2025 - 2031.
- By Indications, the South and Central America Eye Allergy Treatment Market is segmented into Seasonal and Perennial Allergic Conjunctivitis, Vernal Keratoconjunctivitis, Atopic Keratoconjunctivitis, Contact Allergic Conjunctivitis, and Giant Papillary Conjunctivitis. The Seasonal and Perennial Allergic Conjunctivitis segment is projected to expand at a CAGR of 4.9% during 2025 - 2031.
- By Distribution Channel, the South and Central America Eye Allergy Treatment Market is segmented into Hospital Pharmacies, Online Pharmacy, and Drug Stores. The Hospital Pharmacies segment is projected to expand at a CAGR of 4.1% during 2025 - 2031.
By country, the South and Central America Eye Allergy Treatment Market is categorized into Brazil, Argentina, and the Rest of South and Central America. Brazil is projected to expand at a CAGR of 5.0% during 2025 - 2031.
Key players operating in the Eye Allergy Treatment Market are Bayer AG, Santen Pharmaceutical Co., Ltd., AbbVie Inc, Sun Pharmaceutical Industries Ltd, Lupin Ltd, Alcon AG, AdvaCare Pharma USA LLC, Bausch + Lomb Corporation, ZEXUS PHARMA, Grevis Pharmaceuticals Pvt Ltd., among others.
In July 2025, Lupin Limited announced the launch of Loteprednol Etabonate Ophthalmic Suspension, 0.5%, in the United States. Loteprednol Etabonate Ophthalmic Suspension, 0.5% is bioequivalent to Lotemax Ophthalmic Suspension, 0.5%, of Bausch & Lomb Inc.
In May 2024, Santen Pharmaceutical Co., Ltd. and Mitsubishi Tanabe Pharma Corporation announced the launch of Alesion Eyelid Cream 0.5%, an allergic conjunctivitis treatment in Japan. Both companies have already concluded a joint sales promotion contract for the product, which is sold in Japan by Santen.
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com